TauRx Therapeutics Achieves Enrolment Target for Second Phase III Clinical Trial of LMTX™ in Alzheimer’s Disease
Sep 22 - 2014 10:28 AM
TauRx Therapeutics Ltd has achieved its target enrolment of 700 subjects with mild Alzheimer’s disease into the second of its two Phase III clinical trials of LMTX™, a tau aggregation inhibitor, for the treatment of Alzheimer’s disease.
TauRx Therapeutics Achieves Enrolment Target in the First of its Two Phase III Clinical Trials of LMTX™ in Alzheimer’s Disease
Jul 15 - 2014 06:00 AM
TauRx Therapeutics Ltd today announced it has achieved its target enrolment of 833 subjects into one of its two ongoing multi-centre Phase III clinical trials of LMTX™, a tau aggregation inhibitor, for the treatment of Alzheimer’s Disease [AD].
TauRx Chairman to present at scientific symposium focused on advances in Alzheimer’s treatments
Mar 26 - 2014 05:00 AM
Prof. Wischik, Chairman of TauRx Therapeutics, will present a scientific update at the 13th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy on the company’s global Phase 3 clinical trials; its tau aggregation inhibitor, LMTX™, is aimed at halting the progression of Alzheimer’s
TauRx Therapeutics to present at Social Care Conference in London on 25th March
Mar 23 - 2014 05:00 AM
TauRx Chairman and London-based principal investigator will highlight how access to investigational treatments for Alzheimer’s is changing the care model for people with cognitive impairment – now and in the future
Erste deutsche Patienten melden sich zu den klinischen Phase-3-Studien von LMTX™ zur Alzheimer-Krankheit an
Jan 09 - 2014 08:46 AM
Klinische Studien beginnen in Deutschland mit einem Tau-Aggregationshemmer (TAI) der zweiten Generation mit dem Ziel, das Fortschreiten von Alzheimer zu stoppen